LS513Homo sapiens (Human)Cancer cell line
Also known as: LS 513, LS-513
Quick Overview
LS513 is a colorectal cancer cell line used in research for understanding molecular mechanisms and drug responses.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1386 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Intestine, ileocecal valve[UBERON:UBERON_0000569] |
Donor Information
| Age | 63 |
|---|---|
| Age Category | Adult |
| Sex | Male |
| Race | caucasian |
Disease Information
| Disease | Cecum adenocarcinoma |
|---|---|
| Lineage | Bowel |
| Subtype | Colon Adenocarcinoma |
| OncoTree Code | COAD |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000007_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationNone reported | TP53 | - | - | - | PubMed=19787792 |
| MutationSimple | KRAS | p.Gly12Asp (c.35G>A) | Unspecified | - | PubMed=29786757 |
| MutationSimple | CTNNB1 | p.Ala5_Ala80del (c.14_241del228) | Homozygous | - | from parent cell line LS513 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Differential effector engagement by oncogenic KRAS.";
McCormick F.
Cell Rep. 22:1889-1902(2018).
Pharmacoproteomic characterisation of human colon and rectal cancer.
Weichert W., Knapp S., Feller S.M., Kuster B.
Mol. Syst. Biol. 13:951-951(2017).
Genomic determinants of protein abundance variation in colorectal cancer cells.
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.
Cell Rep. 20:2201-2214(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Golub T.R., Root D.E., Hahn W.C.
Sci. Data 1:140035-140035(2014).
Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.
Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.
Clin. Cancer Res. 21:3695-3704(2015).
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.
Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.
Nat. Commun. 6:7002.1-7002.10(2015).
Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.
Mariadason J.M., Sieber O.M.
Cancer Res. 74:3238-3247(2014).
Identification of a microRNA expression signature for chemoradiosensitivity of colorectal cancer cells, involving miRNAs-320a, -224, -132 and let7g.
Grade M., Gaedcke J.
Radiother. Oncol. 108:451-457(2013).
Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines.
Orphanides G., French T., Wessels L.F.A.
BMC Med. Genomics 5:66.1-66.15(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.
Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.
Br. J. Cancer 103:340-346(2010).
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.
Cancer Res. 70:5901-5911(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.
Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.
Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.
Garcia-Foncillas J.
Mol. Cancer 5:29.1-29.10(2006).
Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.
Liu Y., Bodmer W.F.
Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines.
Hamelin R.
Oncogene 20:5025-5032(2001).
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
Wolf E., Gabius H.-J.
J. Cancer Res. Clin. Oncol. 127:375-386(2001).
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines.
Hamelin R.
Cancer Res. 57:300-303(1997).
Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.
Thomas G., Hamelin R.
Oncogene 13:2727-2730(1996).
Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line.
Suardet L., Li C., Little J.B.
Int. J. Cancer 68:126-131(1996).
Responsiveness of three newly established human colorectal cancer cell lines to transforming growth factors beta 1 and beta 2.
Eliason J.F., Odartchenko N.
Cancer Res. 52:3705-3712(1992).